Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis

Nathan Peroutka‐Bigus; Michael S. Sherman; Firat Kaya; Samanthi L. Waidyarachchi; Jiuyu Liu; Joel N. Rushefsky; Michelle M. Butler; Terry L. Bowlin; Bernd Meibohm; Mercedes Gonzalez Juarrero; Anne J. M. Lenaerts; Matthew Zimmerman; Richard E. Lee Jr.; Gregory T. Robertson

doi:10.1128/aac.01183-25

MicrobiologyAntimicrobial Agents and ChemotherapySep 30, 2025

Peer-reviewed journal article

Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis

Nathan Peroutka‐Bigus iD, Michael S. Sherman, Firat Kaya iD, Samanthi L. Waidyarachchi iD, Jiuyu Liu iD, Joel N. Rushefsky, Michelle M. Butler iD, Terry L. Bowlin iD, Bernd Meibohm iD, Mercedes Gonzalez Juarrero iD, Anne J. M. Lenaerts, Matthew Zimmerman iD, Richard E. Lee Jr.iD, Gregory T. Robertson iD

Abstract

Spectinamides have garnered interest as experimental tuberculosis therapeutics owing to their safety profile and efficacy as partner agents when used in conjunction with established regimens in mice. The Nix-TB regimen of bedaquiline, pretomanid, and linezolid represents a short, effective regimen recommended for treatment of pre-extensively drug-resistant tuberculosis. However, linezolid administration is associated with severe adverse events which limits its use. Here we present preclinical data that spectinamide MBX-4888A can replace linezolid in Nix-TB.

PDF DOI